cis-methyl 3-((tert-butoxycarbonyl)amino)cyclopentane-1-carboxylate | 862700-37-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: cis-methyl 3-((tert-butoxycarbonyl)amino)cyclopentane-1-carboxylate
• 英文别名: Methyl 3-((tert-butoxycarbonyl)amino)cyclopentanecarboxylate；methyl 3-[(2-methylpropan-2-yl)oxycarbonylamino]cyclopentane-1-carboxylate
• CAS: 862700-37-6
• 化学式: C₁₂H₂₁NO₄
• 分子量: 243.303
• InChiKey: ZZGMDDXYOHHJMT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  (1S)-(+)-2-氮杂双环[2.2.1]庚-5-烯-3-酮 在 吡啶 、 甲醇 、 4-二甲氨基吡啶 、 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 反应 3.0h， 生成 cis-methyl 3-((tert-butoxycarbonyl)amino)cyclopentane-1-carboxylate 、 trans-methyl 3-((tert-butoxycarbonyl)amino)cyclopentane-1-carboxylate
  参考文献：
  名称：

  WO2019236631A5

  摘要：

  公开号：

  WO2019236631A5

文献信息

• Amine Compounds
  申请人：Ohmori Yutaka

  公开号：US20080200535A1

  公开（公告）日：2008-08-21

  There is provided a compound exhibiting an activity of suppressing immune response with reduced adverse drug reactions, which compound is useful in the chemotherapy for preventing or treating, for example, a wide range of various autoimmune diseases including systemic erythematodes, chronic rheumatoid arthritis, Type I diabetes, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis or other disorders, or chronic inflammatory diseases, or cancers, lymphoma or leukemia, or resistance to organ or tissue transplantation or rejection against transplantation. Novel amine compounds having an S1P1/Edg1 receptor agonist effect, possible stereoisomers or racemic bodies of the compounds, or pharmacologically acceptable salts, hydrates or solvates of the compound, the stereoisomers or the racemic bodies, or prodrugs of the compounds, the stereoisomers, the racemic bodies, the salts, the hydrates or the solvates, are provided.

  提供了一种化合物，具有抑制免疫反应并减少不良药物反应的活性，该化合物在化疗中用于预防或治疗各种自身免疫性疾病，包括系统性红斑狼疮、慢性类风湿关节炎、I型糖尿病、炎症性肠病、胆汁性肝硬化、葡萄膜炎、多发性硬化或其他疾病，慢性炎症性疾病，癌症，淋巴瘤或白血病，器官或组织移植的抗性或对移植的排斥。提供了具有S1P1/Edg1受体激动剂作用的新型胺类化合物，可能是这些化合物的立体异构体或消旋体，或这些化合物、立体异构体或消旋体的药理学上可接受的盐、水合物或溶剂合物，或这些化合物、立体异构体、消旋体、盐、水合物或溶剂的前药。
• Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor
  申请人：Sekiguchi Yoshinori

  公开号：US20080090863A1

  公开（公告）日：2008-04-17

  The present invention encompasses novel substituted pyridine compounds of Formula (I): which act as MCH receptor antagonists. These compositions and pharmaceutical compositions thereof are useful in the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

  本发明涵盖了式（I）的新型取代吡啶化合物，其作为MCH受体拮抗剂。这些组合物及其制药组合物在预防或治疗改善记忆功能、睡眠和觉醒、焦虑、抑郁、情绪障碍、癫痫、肥胖症、糖尿病、食欲和饮食障碍、心血管疾病、高血压、血脂异常、心肌梗死、暴食障碍，包括贪食症、厌食症、精神障碍，包括躁郁症、精神分裂症、谵妄、痴呆、压力、认知障碍、注意力缺陷障碍、物质滥用障碍和运动障碍，包括帕金森病、癫痫和成瘾方面具有用处。
• BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES
  申请人：Duan Jingwu

  公开号：US20070167451A1

  公开（公告）日：2007-07-19

  The present application describes novel barbituric acid derivatives of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, L, R 1 , R 2 , R 3 , R 4 , R 5 , n, W, U, X, Y, Z, U a , X a , Y a , and Z a are defined in the present specification, which are useful as TNF-α converting enzyme (TACE) and matrix metalloproteinases (MMP) inhibitors.

  本申请描述了新型的巴比妥酸衍生物式I：或其药物可接受的盐或前药形式，其中A、B、L、R1、R2、R3、R4、R5、n、W、U、X、Y、Z、Ua、Xa、Ya和Za在本说明书中有定义，它们可用作TNF-α转化酶（TACE）和基质金属蛋白酶（MMP）抑制剂。
• Novel quinoxalinone derivatives
  申请人：Hirai Hiroshi

  公开号：US20090137597A1

  公开（公告）日：2009-05-28

  A quinoxalinone derivative of the formula (I): or a pharmaceutically acceptable salt or ester thereof, wherein; X is NH, S or the like; Y is O or the like; the partial structure is, for example, the formula: B 1 , B 2 , . . . , B n−1 and B n , (in which n is 4, 5 or 6) are each independently CH, N or the like; B′ 1 , B′ 2 , . . . , B′ n−1 and B′ n (in which n is 4, 5 or 6) are each independently hydrogen or the like; and R is hydrogen, lower alkyl or the like.

  化合物的名称为喹诺酰喹啉酮衍生物，化学式为（I），或其药学上可接受的盐或酯，其中：X为NH，S或类似物；Y为O或类似物；部分结构如下所示，例如公式：B1，B2，...，Bn-1和Bn（其中n为4、5或6）分别独立地为CH、N或类似物；B'1，B'2，...，B'n-1和B'n（其中n为4、5或6）分别独立地为氢或类似物；R为氢、低碳基或类似物。
• CYCLOALKANE-1,3-DIAMINE DERIVATIVE
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP3892278A1

  公开（公告）日：2021-10-13

  The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. wherein, in the formula (1), the dotted circle, R1, R2, R3, R4, R5, R6, R7, R8, Ring Q1, W, m and n are each as defined in the description.

  本发明提供了一种化合物或其药学上可接受的盐，对 Menin 与 MLL 蛋白之间的相互作用具有抑制作用。式（1）所代表的化合物或其药学上可接受的盐。 其中，在式(1)中，虚圈、R1、R2、R3、R4、R5、R6、R7、R8、环Q1、W、m和n各自如描述中所定义。